GLP-1 RA have demonstrated significant cardiovascular protective effects, reducing the risk of major adverse cardiovascular events (MACE) in individuals with or at high risk for atherosclerotic cardiovascular disease (ASCVD), including those with T2DM [13]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.